BAMCO, Inc. - Baron Emerging Markets Fund on Divi's Laboratories Limited
Thesis
Divi's is a leading global manufacturer of active pharmaceutical ingredients and intermediates with strong process chemistry and manufacturing capabilities. Baron sees it as a beneficiary of pharmaceutical supply-chain diversification away from China and highlights its role in oral and injectable GLP-1 supply chains. The manager expects mid-teens compound revenue growth and 20% earnings growth over the next three to five years.
“We expect the company to deliver mid-teens compound revenue growth and 20% earnings growth over the next three to five years.”